Skip to content
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute

Costs and buRdens of Illnesses from a Societal Perspective (CrISP)  Portfolio

The CHOICE faculty are some of the leading experts in the world in establishing the economic costs and burdens of illnesses. They have contributed to the theory of what and how to measure these outcomes and standardized guidelines to apply these methods. The CrISP umbrella highlights CHOICE faculty’s methodological and applied works, where they have estimated the costs and burdens for different illnesses from a societal perspective.

* CHOICE faculty, post-doc or students bolded

Alzheimer’s and Related Dementia

  1. White L, Fishman P, Basu A, Crane PK, Larson EB, Coe NB. Medicare expenditure attributable to dementia. Health Services Research. 2019; 54(4): 773-781. PubMed
  2. White L, Fishman P, Basu A, Crane PK, Larson EB, Coe NB. Dementia is associated with earlier mortality for men and not women in the United States. Gerontology and Geriatric Medicine 2020; 6: 1-7. PubMed
  3. Coe NB, White L, Basu A, Larson EB. Public spending on acute and long-term care for Alzheimer’s and related dementias. Alzheimer’s & Dementia 19(1):150-157. PubMed
  4. Li J, Wang S, Nicholas LH. Management of Financial Assets by Older Adults With and Without Dementia or Other Cognitive Impairments. JAMA Network Open. 2022 September 1;5(9):e2231436. PubMed
  5. Zhang Y, Shao H, Zhang M, Li J. Healthcare Utilization and Mortality After Hospice Live Discharge Among Medicare Patients With and Without Alzheimer’s Disease and Related Dementias. Journal of General Internal Medicine. 2023 January 17. PubMed
  6. Qian Y, Chen X, Tang D, Kelley AS, Li J. Prevalence of Memory-Related Diagnoses Among U.S. Older Adults With Early Symptoms of Cognitive Impairment. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2021 September 13;76(10):1846-1853. PubMed
  7. Li J, Andy C, Mitchell S. Use of Medicare’s New Reimbursement Codes for Cognitive Assessment and Care Planning, 2017-2018. JAMA Network Open. 2021 September 1;4(9):e2125725. PubMed
  8. Li J, Llibre-Guerra JJ, Harrati A, Weiss J, Jiménez-Velázquez IZ, Acosta D, Llibre-Rodriguez JJ, Liu MM, Dow WH. Associations between education and dementia in the Caribbean and the United States: An international comparison. Alzheimer’s & Dementia. 2021;7(1):e12204. PubMed
  9. Choi NS, Li T, Pan J, Yue S, Li J. COVID-19 Stay-At-Home Orders and Older Adults’ Cognitive Health—United States, June 2018–February 2022. China CDC Weekly. 2022 Nov 11;4(45):1002-6. PubMed
  10. McLaughlin T, Feldman H, Fillit H, Sano M, Schmitt F, Aisen P, Leibman C, Mucha L, Ryan JM, Sullivan SD, Spackman DE, Neumann PJ, Cohen J, Stern Y. Dependence as a unifying construct in defining Alzheimer’s disease severity. Alzheimer’s and Dementia. 2010 Nov 6;(6):482-489. PubMed
  11. Bloudek L, Spackman DE, Blankenberg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease.  Journal of Alzheimer’s Disease 2011;26(4):627-45. PubMed
  12. GBD 2019 Ageing Collaborators: Tyrovolas S, Stergachis A, Varsha K, Chang AY, Skirbekk V, Dieleman J, Somanth C, GBD Aging Collaborators, Kotsakis GA, Kassebaum N.  Global, regional, and national sex-specific mortality, life expectancy, and non-fatal burden of diseases and injuries for adults 70 years and older: a systematic analysis for the Global Burden of Disease 2019 Study.  BMJ. 2022 Mar 10;376:e068208. PubMed.
  13. Lee W, Gray SL, Barthold D, Maust DT, Marcum ZA. “Association between informant-reported sleep disturbance and incident dementia: an analysis of the National Alzheimer’s Coordinating Center Uniform Data Set,” Journal of Applied Gerontology, 2022; 41(1): 285-294. PubMed
  14. Barthold D, Gibbons LE, Marcum ZA, Gray SL, Keene CD, Grabowski TJ, Postupna N, Larson EB, Crane PK, “Alzheimer’s disease related neuropathology among patients with medication treated type 2 diabetes in a community-based autopsy cohort,” Journal of Alzheimer’s Disease, 2021; 83(3): 1303-1312, PubMed
  15. Zhou J, Walker RL, Gray SL, Marcum ZA, Barthold D, Bowen JD, McCormick W, McCurry SM, Larson EB, Crane P. “Glucose-dementia association is consistent over blood pressure/antihypertensive groups,” Journal of Alzheimer’s Disease, 2021; 80(1): 79-90. PubMed
  16. Van Dalen JW, Marcum ZA, Gray SL, Barthold D, Moll van Charante EP, Van Gool WA, Crane PK, Larson EB, Richard E. “Association of angiotensin-II stimulating antihypertensive use and dementia risk: post hoc analysis of the PreDIVA trial,” Neurology, 2021; 96(1): e67-e80; PubMed
  17. Marcum ZA, Chang CY, Barthold D, Homes HM, Lo-Ciganic WH. “Industry Payments to Physicians and Prescribing Branded Memantine and Donepezil Combination,” Neurology: Clinical Practice, 2021; 11(3): 181-187, PubMed
  18. Barthold D, Marcum ZA, Chen S, White L, Ailabouni N, Basu A, Coe NB, Gray SL. “Difficulty with taking medications is associated with future diagnosis of Alzheimer’s disease and related dementias,” Journal of General Internal Medicine, 2021; 36(4): 863-868. PubMed
  19. Thunell J, Chen Y, Joyce G, Barthold D, Shekelle PG, Brinton RD, Zissimopoulos J. “Drug therapies for chronic conditions and risk of Alzheimer’s disease and related dementias: a scoping review,” Alzheimer’s & Dementia, 2021; 17(1): 41-48, PubMed
  20. Lee W, Gray SL, Zaslavsky O, Barthold D, Marcum ZA. “Association between having a family member with dementia and perceptions of dementia preventability,” Aging and Mental Health, 2020; 26(2): 270-276, PubMed
  21. Barthold D, Joyce G, Ferido P, Drabo EF, Marcum ZA, Gray SL, Zissimopoulos J. “Pharmaceutical treatment for Alzheimer’s disease and related dementias: utilization and disparities,” Journal of Alzheimer’s Disease, 2020; 76(2): 579-589. PubMed
  22. Barthold D, Marcum ZA, Gray SL, Zissimopoulos J. “Alzheimer’s disease and related dementias risk: comparing users of non-selective and M3-selective bladder antimuscarinic drugs,” Pharmacoepidemiology & Drug Safety, 2020; 29(12): 1650-1658, PubMed
  23. Salas J, Morley JE, Scherrer JF, Floyd JS, Farr SA, Zubatsky M, Barthold D, Dublin S. “Risk of incident dementia following metformin initiation compared with noninitiation or delay of antidiabetic medication therapy,” Pharmacoepidemiology and Drug Safety, 2020; 29(6): 623-634, PubMed
  24. Barthold D, Joyce G, Brinton RD, Wharton W, Kehoe PG, Zissimopoulos J. “Association of combination statin and antihypertensive therapy with reduced Alzheimer’s disease and related dementia risk,” PLOS ONE, 2020; 15(3): e022954, Special collection on early diagnosis and treatment of Alzheimer’s disease, PubMed
  25. Lee W, Gray SL, Barthold D, Crane P, Larson EB, Marcum ZA. “Do Patient Concerns about Antihypertensive Use for Dementia Prevention vary by Current Use of Antihypertensive?” Patient Preference and Adherence, 2019; 13: 1809-1815, PubMed
  26. Drabo EF, Barthold D, Joyce G, Ferido P, Chui HC, Zissimopoulos J. “Longitudinal analysis of dementia diagnosis and specialty care among racially diverse Medicare beneficiaries,” Alzheimer’s & Dementia, 2019; 15(11): 1402-1411, PubMed
  27. Marcum ZA, Hohl SD, Barthold D, Zaslavksy O, Larson EB, Gray SL. “Beliefs about benefits and harms of medications and supplements for brain health,” Preventive Medicine Reports, 2020; 17, 101060, PubMed
  28. Marcum ZA, Hohl SD, Gray SL, Barthold D, Crane PK, Larson EB. “Patient perceptions of antihypertensive use as a dementia prevention strategy: a mixed-method analysis of a web-based survey,” Journal of Alzheimer’s Disease, 2019 ;68(2): 523-529, PubMed
  29. Marcum ZA, Hohl SD, Gray SL, Barthold D, Crane PK, Larson EB. “Brain health and dementia prevention: a mixed-method analysis,” American Journal of Health Behavior, 2019; 43(2): 300-310, PubMed
  30. Barthold D, Joyce G, Wharton W, Kehoe P, Zissimopoulos J. “The association of multiple anti-hypertensive medication classes with Alzheimer’s disease incidence across sex, race, and ethnicity,” PLOS ONE, 2018; 13(11): e0206705, PubMed
  31. Zissimopoulos J, Barthold D, Brinton RD, Joyce G. “Sex and race differences in the association of statin use and incidence of Alzheimer’s disease,” JAMA Neurology, 2017; 74(2): 225-232, PubMed
  32. Boustani M, Doty EG, Garrison LP Jr, et al. Assessing the Cost-effectiveness of a Hypothetical Disease-Modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease. Clin Ther. 2022 Oct 6:S0149-2918(22)00322-8. doi: 10.1016/j.clinthera.2022.09.008 PubMed
  33. Park YP, Marcum ZA, Garrison LP. Toward a broader concept of societal value: family spillovers in Alzheimer’s Disease. J Tech Assess in Health Care.  38 e7, 1-PubMed


  1. Weiss KB, Sullivan SD. The economic costs of asthma: a review and conceptual model. Pharmacoeconomics, 1993;4(1):14-30. PubMed
  2. Weiss KB, Buist AS, Sullivan SD. Asthma’s Impact on Society: The Social and Economic Burden. 1999. Lung Biology in Health and Disease. Vol. 138. New York, NY: Marcel Dekker, Inc. URL
  3. Weiss KB, Sullivan SD, Lyttle CS. Trends in the costs of asthma in the United States, 1985-1994. Journal of Allergy and Clinical Immunology 2000;106(3):493-499. PubMed
  4. Weiss KB, Sullivan SD. The health economics of asthma and allergic rhinitis: Part I. Assessing the economic impact. Journal of Allergy and Clinical Immunology 2001;107(1):3-8. PubMed
  5. Sullivan SD, Weiss KB. The health economics of asthma and allergic rhinitis: Part II. Journal of Allergy and Clinical Immunology 2001;107(2):203-210. PubMed
  6. Sullivan SD, Rasouliyan L, Russo PA, Kamath T, Chipps B. The burden of uncontrolled disease in severe or difficult-to-treat asthma. Allergy 2007;62:126-133. PubMed
  7. Wertz DA, Pollock M, Rodgers K, Bohn R, Sullivan SD. Impact of asthma control on sleep, attendance at work, normal activities, and disease burden. Annals of Allergy 2010 105(2):118-23. PubMed

Cardiovascular disease

  1. Coleman KJ, Fischer H, Arterburn DE, Barthold D, Barton LJ, Basu A, Courcoulas A, Crawford CL, Fedorka P, Kim B, Mun E, Murali S, Reynolds K, Suh K, Wei R, Yoon TK, Zane R. “Effectiveness of gastric bypass versus gastric sleeve for cardiovascular disease (ENGAGE CVD): protocol and baseline result for a comparative effectiveness study,” JMIR Research Protocols, 2020; 9(4): e14936, PubMed
  2. Basu A, Barton LJ, Fischer H, Reynolds K, Arterburn DE, Barthold D, Courcoulas A, Crawford CL, Fedorka PN, Kim BB, Mun EC, Murali SB, Zane RE, Coleman KJ. “Comparative Effectiveness of Gastric Bypass and Sleeve Gastrectomy on Predicted 10-Year Risk of Cardiovascular Disease 5 Years Following Surgery,” Surgery for Obesity and Related Diseases, 2022; 18(6): 716-726. PubMed
  3. Xie J, Wang Y, Xu Y, Fine JT, Lam J, Garrison LP. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial. J Med Econ. 2022 Jan-Dec;25(1):51-58.PubMed
  4. Garrison LP Jr, Lewin J, Young CH, Généreux P, Crittendon J, Mann MR, Brindis RG. The clinical and cost burden of coronary calcification in a Medicare cohort: An economic model to address under-reporting and misclassification. Cardiovasc Revasc Med. 2015 Oct-Nov;16(7):406-12.. Epub 2015 Aug 12. PubMed
  5. Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP. Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.  Pharmacoepidemiology and Drug Safety, 2014.PubMed


  1. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating chronic obstructive pulmonary disease in the United States. Chest 2001;119:344-352. PubMed
  2. Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. European Respiratory Journal 2003;21(Suppl 41):29s-35s PubMed
  3. Buist AS, Vollmer WM, Sullivan SD, Weiss KB, Lee TA, Menezes AM, Crapo RO, Jensen RL, Burney PG. The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. COPD 2005;2(2):277-283. PubMed
  4. Woo L, Smith HE, Sullivan SD. The economic burden of chronic obstructive pulmonary disease in the Asia-Pacific region: A systematic review. Value in Health Regional Issues 2019 May 18:121-131. PubMed


  1. Basu A. Estimating the Infection Fatality Rate among Symptomatic Covid-19 Cases in the U.S. Health Affairs 39:1229–1236. PubMed
  2. Karaca-Mandic P, Sen S, Georgiou A, Zhu Y, Basu A. Association of COVID-19-related hospital use and overall COVID-19 mortality in the United States. Journal of General Internal Medicine 2020; 19: 1-3. PubMed
  3. Basu A, Gandhay VJ. Quality-adjusted life year losses averted with every Covid-19 infection prevented in the U.S. Value in Health 2021; 24(5):632-640. PubMed
  4. Choi NS, Li T, Pan J, Yue S, Li J. COVID-19 Stay-At-Home Orders and Older Adults’ Cognitive Health—United States, June 2018–February 2022. China CDC Weekly. 2022 Nov 11;4(45):1002-6. PubMed


  1. Huang ES, Basu A, Finch M, Frytak J, Manning WG. The complexity of medication regimens and test ordering for patients with diabetes from 1995 to 2003. Current Medical Research and Opinion 2007; 23(6): 1423-1430. PubMed
  2. Huang E, Basu A, O’Grady M, Capretta J. Projecting the future diabetes population size and related costs for the United States. Diabetes Care 2009; 32:2225-2229. PubMed
  3. Flory JH, Li J, Dawwas GK, Leonard CE. Compared to commercially insured patients, Medicare advantage patients adopt newer diabetes drugs more slowly and adhere to them less. Endocrinology, Diabetes & Metabolism. 2021 July;4(3):e0024 PubMed
  4. Barthold D, Brouwer E, Barton LJ, Arterburn DE, Basu A, Courcoulas A, Crawford CL, Fedorka PN, Fischer H, Kim BB, Mun EC, Murali SB, Reynolds K, Yoon TK, Zane RE, Coleman KJ. “Minimum threshold of bariatric surgical weight loss for diabetes remission,” Diabetes Care, 2022; 45(1): 92-99. PubMed
  5. Barthold D, Chiguluri V, Gumpina R, Castro Sweet C, Pieratt J, Cordier T, Matanich R, Rogstad T, Prewitt T. “Health care utilization and medical cost outcomes from digital diabetes prevention program in a Medicare Advantage population,” Population Health Management, 2020; 23(6): 414-421. PubMed
  6. Rumball-Smith J, Barthold D, Nandi A, Heymann J. “Diabetes associated with early labor force exit: a cross-national comparison of 16 high-income countries,” Health Affairs, 2014; 33(1): 110-115, PubMed
  7. Wallick C, Hansen RN, Campbell J, Kiss S, Kowalski J, Sullivan SD. A Cohort Study of Comorbidity and Healthcare Resource Use Associated with Diabetic Macular Edema among Commercially-Insured Diabetics. Ophthalmic Surgery, Lasers and Imaging Retina 2015;46(7):744-51. PubMed


  1. Coleman KJ, Basu A, Barton LJ, Fischer H, Arterburn DE, Barthold D, Courcoulas A, Crawford CL, Kim BB, Fedorka PN, Mun EC, Murali SB, Reynolds K, Zane RE, Alskaf S. “Remission and relapse of dyslipidemia following Vertical Sleeve Gastrectomy vs Roux-en-Y Gastric Bypass in a racially/ethnically diverse population,” JAMA Network Open, 2022; 5(9): e2233843. PubMed
  2. Nichols GA, Arondekar B, Garrison LP Jr. Patient characteristics and medical care costs associated with hypertriglyceridemia. Am J Cardiol. 2011 Jan 15;107(2):225-9. PubMed


  1. Reynolds K, Barton LJ, Basu A, Fischer H, Arterburn DE, Barthold D, Courcoulas A, Crawford CL, Kim BB, Fedorka PN, Mun EC, Murali SB, Zane RE, Coleman KJ. “Comparative Effectiveness of Gastric Bypass and Vertical Sleeve Gastrectomy for Hypertension Remission and Relapse: The ENGAGE CVD Study,” Hypertension, 2021; 78(4): 1116-1125, PubMed
  2. Jiang S, Seslar SP, Sloan LA, Hansen RN. Healthcare Resource Utilization and Costs Associated with Atrial Fibrillation and Rural-urban Disparities. Journal of Managed Care and Specialty Pharmacy 2022;28(11):1321-30. PubMed


  1. Hansen RN, Pham AT, Boing EA, Lovelace B, Wan GJ, Urman RD. Reduced Length of Stay and Hospitalization Costs among Inpatient Hysterectomy Patients with Postoperative Pain Management including IV versus Oral Acetaminophen. PLOS ONE 2018;13(9):e0203746. PubMed
  2. Mont MA, Lovelace B, Pham AT, Hansen RN, Chughtai M, Gwam CU, Khlopas A, Barrington JW. Intravenous Acetaminophen May Be Associated with Reduced Odds of 30-Day Readmission after Total Knee Arthroplasty. Journal of Knee Surgery 2019 May;32(5):414-420:Epub 2018 May 7. PubMed
  3. Barrington JW, Hansen RN, Lovelace B, Böing EA, Chughtai M, Newman JM, Pham AT, Khlopas A, Sodhi N, Sultan AA, Mont MA. Impact of Intravenous Acetaminophen on Lengths of Stay and Discharge Status after Total Knee Arthroplasty. Journal of Knee Surgery 2018;32(1):111-116. PubMed
  4. Hansen RN, Pham AT, Boing EA, Lovelace B, Wan GJ, Miller TE. Comparative Analysis of Length of Stay, Hospitalization Costs, Opioid Use, and Discharge Status among Spine Surgery Patients with Postoperative Pain Management including IV versus Oral Acetaminophen. Current Medical Research & Opinion 2017;33(5):943-948. PubMed
  5. Hansen RN, Pham A, Strassels SA, Balaban S, Wan GJ. Comparative Analysis of Length of Stay and Inpatient Costs for Orthopedic Surgery Patients Treated with IV Acetaminophen and IV Opioids versus IV Opioids Alone for Postoperative Pain. Advances in Therapy 2016;33(9):1635-45. PubMed
  6. Hansen RN, Pham AT, Boing EA, Lovelace B, Wan GJ, Thomas DA, Fontes ML. Hospitalization Costs and Resource Allocation in Cholecystectomy with Use of Intravenous versus Oral Acetaminophen. Current Medical Research & Opinion 2018;34(9);1549-1555. PubMed

Mental Illnesses

  1. Van Voorhees BW, Ellis JM, Gollan J, Basu A. Predicting future risk of depressive episode in adolescents: the Chicago Adolescent Depression Risk Assessment (CADRA). Annals of Family Medicine 2008 Nov-Dec;6(6):503-511. PubMed
  2. Correll CU, Chepke C, Gionfriddo P, Parks J, Foxworth P, Basu A, Brister TS, Brown D, Clarke C, Hassoun Y. The post COVID-19 healthcare landscape and the use of long-acting injectable antipsychotics for individuals with schizophrenia and bipolar I disorder: the importance of an integrated collaborative-care approach. BMC Psychiatry2022;22(1):32. PubMed


  1. Stokes M, Becker WJ, Lipton RB, Sullivan SD, et al. Cost of Healthcare Among Patients With Chronic and Episodic Migraine in Canada and the United States: Results From the International Burden of Migraine Study (IBMS). Headache 2011;51:1058-1077 PubMed
  2. Lee JH, Shewale AR, Barthold D, Devine EB. “Geographic variation in the use of triptans and opioids for acute treatment of migraine attacks,” Headache, 2021; 61(10): 1499-1510, PubMed


  1. Brouwer E, Yeung K, Barthold D, Hansen R. “Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in one mid-size integrated health system,” Journal of Managed Care and Specialty Pharmacy, 2021; 27(6): 732-742, PubMed
  2. Pocobelli G, Akosile MA, Hansen RN, Eavey J, Wellman RD, Johnson RL, Carls G, Bron M, Dublin S. Obstructive Sleep Apnea and Risk of Motor Vehicle Accident. Sleep Medicine 2021;85:196-203. PubMed
  3. Gold LS, Nazareth TA, Yu T, Fry KR, Mahler N, Rava A, Waltrip RW, Hansen RN. Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms. Pediatric Health, Medicine and Therapeutics 2019;10:195-207. PubMed
  4. Hepp Z, Dodick DW, Varon SF, Gillard P, Mathew N, Chia J, Hansen RN, Devine EB. Persistence and Switching Patterns Among Patients with Chronic Migraine: A Retrospective Claims Analysis. Cephalagia 2017;37(5):470-85. PubMed
  5. Gold LS, Suh, K, Schepman, PB, Damal K, Hansen RN. Health Care Costs and Resource Utilization in Multiple Sclerosis Relapse Patients. Advances in Therapy 2016;33(8):1279-92. PubMed
  6. Gold LS, Schepman, PB, Wang WJ, Philbin M, Niewoehner J, Damal K, Hansen RN. Healthcare Costs and Resource Utilization in Infantile Spasms Patients Treated with H.P. Acthar Gel. Advances in Therapy 2016;33(8):1293-304. PubMed
  7. van der Goes DN, Ney JP, Garrison LP. Determinants of specialist physician ambulatory visits: a neurology example. J Med Econ. 2019 Jun 18:1-10.PubMed


  1. Chin L, Hansen RN, Carlson JJ. Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis. J Manag Care Spec Pharm. 2020;26(8):962-70. PubMed
  2. Yu JS, Hansen RN, Valderrama A, Carlson JJ. Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma. Leuk Lymphoma. 2016:1-8. PubMed
  3. Hendrix N, Oestreicher N, Lalla D, Dolan CM, Fisher KA, Veenstra DL, Moy B. Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. Clin Breast Cancer. 2022 PubMed
  4. Ko GC, Hansen RN, Carlson JJ. Comparing Costs and Healthcare Resource Utilization Between nmHSPC and mHSPC Patients: A Retrospective Claims Analysis. Journal of Managed Care and Specialty Pharmacy 2022;28(3):287-95. PubMed
  5. Hansen RN, Zhang Y, Seal B, Ryan K, Yong C, Darilay A, Ramsey SD. Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis. BMC Cancer 2020;20(1):276. PubMed
  6. Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD. Healthcare Costs Among Renal Cancer Patients Using Pazopanib and Sunitinib. Journal of Managed Care and Specialty Pharmacy 2015;21(1):37-44. PubMed

Sickle Cell Disease

  1. Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu A. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Advances 2022; May 16:bloodadvances.2021006281. PubMed
  2. Jiao B, Basu A, Ramsey S, Roth J, Bender MA, Quach D, Devine B.  Health State Utilities for Sickle Cell Disease: A Catalog Prepared from a Systematic Review. Value In Health 2022; 25(2):276-287. PubMed
  3. Baldwin Z, Jiao B, Basu A, Roth J, Bender MA, Elsisi Z, Johnson KM, Cousin E, Ramsey SD, Devine B. Medical and Non-Medical Costs of Sickle Cell Disease and Treatments: A Systematic Review and Landscape Analysis. PharmacoEconomics Open 6(4):469-481. PubMed
  4. Ramsey SD, Bender MA, Li L, Johnson KM, Jiao B, Devine B, Basu A. Prevalence of comorbidities associated with sickle cell disease among non-elderly individuals with commercial insurance – A retrospective cohort study. PLoS One 17(11):e0278137. PubMed
  5. Jiao B, Johnson KM, Ramsey SD, Bender MA, Devine B, Basu A. Long-Term Survival of Individuals with Sickle Cell Disease: A Nationwide Cohort Study of Medicare and Medicaid Beneficiaries. Blood Advances 2023; In Press. PubMed

Pain Management (Opioids)

  1. Gold LS, Strassels SA, Hansen RN. Healthcare Costs and Utilization in Patients Receiving Prescriptions for Long-Acting Opioids for Acute Post-Surgical Pain. Clinical Journal of Pain 2016;32(9):747-54. PubMed
  2. Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic Costs of Non-Medical Use of Prescription Opioids. Clinical Journal of Pain 2011;27(3):194-202. PubMed
  3. Kleykamp BA, Dworkin RH, Turk DC, … Garrison LP et al. Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT Recommendations. Pain. 2021 Sep 9. PubMed
  4. Garrison LP, Schepman P, Bushmakin AG, et al. patients with osteoarthritis: an exploratory, real-world data analysis. Qual Life Res. 2021 Jul 5. doi: 10.1007/s11136-021-02907-0. Epub ahead of print. PMID: 34219192.PubMed
  5. Yenikomshian MA, White AG, Carson ME, Garrison LP, Oderda GM, Biskupiak JE, Hlavacek PR, Roland CL. Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients. J Opioid Manag. 2017 Sep/Oct;13(5):291-301 PubMed
  6. Banerjee S, Roland C, Willke R, Mardekian J, Garrison L. Prevalence of and comorbid health conditions associated with pediatric prescription opioid use in the US. J Pain. 2016 Apr;17(4S):S33-S34PubMed

Social Determinants of Health

  1. Zhang Y, Li J (joint first author), Yu J, Braun RT, Casalino LP. Social Determinants of Health and Geographic Variation in Medicare per Beneficiary Spending. JAMA network open. 2021 June 1;4(6):e2113212. PubMed
  1. Li J, Llibre-Guerra JJ, Harrati A, Weiss J, Jiménez-Velázquez IZ, Acosta D, Llibre-Rodriguez JJ, Liu MM, Dow WH. Associations between education and dementia in the Caribbean and the United States: An international comparison. Alzheimer’s & Dementia. 2021;7(1):e12204. PubMed
  2. Li J, Dow WH, Rosero-Bixby L. Education gains attributable to fertility decline: Patterns by gender, period, and country in Latin America and Asia. Demography. 2017 Aug 1;54(4):1353-73. PubMed

Oral Health

  1. Hansen RN, Shirtcliff RM, Ludwig S, Dysert J, Allen G, Milgrom P. Changes in Silver Diamine Fluoride Use and Dental Care Costs: A Longitudinal Study. Pediatric Dentistry 2019;41(1):35-39. PubMed
  2. Hansen RN, Shirtcliff RM, Dysert J, Milgrom PM. Costs and Resource Use Among Child Patients Receiving Silver Nitrate/Fluoride Varnish Caries Arrest. Pediatric Dentistry 2017;39(4):304-7. PubMed


  1. Kim E, Marcum ZA, Raimundo K, Veenstra DL. Health care utilization and expenditures of parents of children with and without hemophilia A. J Manag Care Spec Pharm. 2022 May;28(5):529-537. PubMed
  2. Thornburg CD, Adamski K, Cook K, … Garrison LP, Croteau SE. Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. J Manag Care Spec Pharm 2021 Dec 27:1-12.
  3. Beal B, Shih V, Campbell J, Veenstra D, Devine B. Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study. Clin Ophthalmol. 2021 Feb 9;15:453-460. PubMed
  4. Yeung K, Barthold D, Dusetzina S, Basu A. “Patient and plan spending after passage of state specialty drug access laws,” New England Journal of Medicine, 2020; 383(6): 558-566. PubMed
  5. Song Y, Barthold D. “The effects of state‐level pharmacist regulations on generic substitution of prescription drugs,” Health Economics, 2018; 27(11): 1717-1737, PubMed
  6. Barthold D, Nandi A, Mendoza Rodríguez J, Heymann J. “Analyzing whether countries are equally efficient at improving longevity for men and women,” American Journal of Public Health, 2014; 104(11): 2163-2169, PubMed

Methodology Works

  1. Meltzer D, Basu A, and Conti R. The Economics of Comparative Effectiveness Studies: Societal and Private Perspectives. Draft manuscript prepared at the request of the I.O.M. Roundtable on Evidence-Based Medicine, University of Chicago, 2007. URL
  2. Meltzer D, Basu A, Sculpher M. Theoretical foundations in cost-effectiveness analysis. In. Second Panel on Cost-effectiveness Analysis in Health and Medicine (ed. Neumann et al.) Oxford University Press, 2016. URL
  3. Basu A. Estimating Costs and Valuations of Non-Health Benefits in Cost-Effectiveness Analysis. In. Second Panel on Cost-effectiveness Analysis in Health and Medicine (ed. Neumann et al.) Oxford University Press, 2016.URL
  4. Basu A, Meltzer D. Modeling comparative effectiveness and the value of research. Annals of Internal Medicine (Editorial) 2009; 151: 210-211. PubMed
  5. Basu A. Patient-centered or “central” patient: Raising the veil of ignorance over randomization. Statistics in Medicine (Commentary) 2012; 31: 3054-3056. PubMed
  6. Basu A, Manning WG, Mullahy J. Comparing alternative models: log vs Cox proportional hazard? Health Economics 2004; 13(8): 749-765.  PubMed
  7. Basu A, Rathouz P. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics 2005; 6(1): 93-109. PubMed
  8. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes. 2003 NBER Working Paper t0293. Journal of Health Economics 2005; 24(3): 465-488. PubMed
  9. Basu A Extended generalized linear models: Simultaneous estimation of link and variance functions. The Stata Journal 2005; 5(4): 501-516. URL
  10. Basu A, Arondekar BV, Rathouz P. Scale of interest versus scale of estimation: Comparing alternative estimators for the incremental costs of a comorbidity. Health Economics 2006; 15(10): 1091-1107. PubMed
  11. Basu A, Manning WG. A test for proportional hazards assumption within the class of exponential conditional mean framework. Health Services and Outcomes Research Methodology 2006; 6(3-4): 81-100. URL
  12. Basu A, Manning WG. Issues for the next generation of healthcare costs analyses. Medical Care 2009; 47(7_Supplement_1):S109-S114. PubMed
  13. Basu A, Manning WG. Estimating life-time or episode cost of illness under censoring. York Health Econometrics and Data Group (HEDG) Working Paper 09/09. Health Economics 2010; 19(9): 1010-1028. PubMed
  14. Basu A, Polsky D, Manning WG. Estimating treatment effects on healthcare costs under exogeneity: Is there a ‘magic bullet’? York Health Econometrics and Data Group (HEDG) Working Paper 08/11; 2008 NBER Working Paper w14086. Health Services and Outcomes Research Methodology 2011; 11:1-26. PubMed
  15. Borah B, Basu A. Highlighting differences between conditional and unconditional quantile regression approaches through an application to assess medication adherence. Health Economics 2013; 22(9): 1052-1070. PubMed
  16. Kim DD, Basu A. Estimating the medical care costs of obesity in the U.S.: Systematic review, meta-analysis and empirical analysis. Value in Health 2016; 19: 602-613. PubMed
  17. Park S, Basu A. Alternative evaluation metrics for risk adjustment methods. Health Economics 2018; 27(6): 984-1010. PubMed
  18. Wang W-J, Devine B, Bansal A, White HS, Basu A. Meta‐Analyzing count events over varying durations using the piecewise Poisson model: The case for post stroke seizures. Research Synthesis Methods 2021; 12(3):347-356. PubMed
  19. Park S, Basu A. Improving risk adjustment with machine learning: accounting for service-level propensity scores to reduce service-level selection. Health Services and Outcomes Research 2021; 21:363-388. URL
  20. Basu A, Manca A. Regression estimators for generic health-related quality of life and quality-adjusted life-years. Medical Decision Making 2012; 32(1):56-69. PubMed
  21. Basu A, Carlson JJ, Veenstra DL. Health Years in Total (H.Y.T.): A new health objective function for cost-effectiveness analysis. Value In Health 2020; 23(1):96-103. PubMed
  22. Jiao B, Basu A. Catalog of age- and medical-condition­-specific healthcare costs in the U.S. to inform future costs calculations in cost-effectiveness analysis. Value in Health 2021; 24(7):957-965. PubMed
  23. Jiao B, Basu A. Associating Health-Related Quality of Life with Time Use in the United States to Inform Productivity and Time Costs Calculation in Cost-Effectiveness Analysis. PharmacoEconomics. 2023. In Press. PubMed
  24. Zhang Y, Gupta A, Nicholson S, Li J. Elevated end-of-life spending: A new measure of potentially wasteful health care spending at the end of life. Health services research. 2023 February;58(1):186-194. PubMed
  25. Bloudek L, Spackman DE, Veenstra DL, Sullivan SD. CDR State Transition Probabilities in Alzheimer’s Disease with and without Cholinesterase Inhibitor Intervention in an Observational Cohort of AD Patients in the NACC-UDS Database. Journal of Alzheimer’s Disease 2011;24(3):599-607. PubMed
  26. Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. Measuring Alzheimer disease progression with transition probabilities: Estimates from NACC-UDS. Current Alzheimer Research 2012 9(9):1050-1058. PubMed
  27. Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD.  The validity of dependence as a health outcome measure in Alzheimer disease. American Journal of Alzheimer’s Disease and Other Dementias 2013 May;28(3):245-52. PubMed
  28. Browne AJ, Chipeta MG, Haines-Woodhouse G, Kumaran EPA, Hamadani BH, Zaraa S, Henry NJ, Deshpande A, Reiner RC, Day NPG, Lopez AD, Dunachie S, Moore CE, Stergachis A, Hay SI, Dolecek C. Global antibiotic consumption in humans, 2000 to 2018: a spatial modelling study.  Lancet Planetary Health.  2021 Nov 11:S2542-5196(21)00280-1.  PubMed
  29. Coyle D, Durand-Zaleski I, Farrington J, Garrison L, et al. HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. Eur j Health Econ. 2020 Aug 13 PubMed
  30. Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL. Economic Analysis of Vaccination Programs. Value Health. 2018 Oct;21(10):1133-1149. PubMed
  31. Garrison LP, Kamal-Bahl, S, Towse, A. Toward a Broader Concept of Value:  Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis. Value in Health 20 (2017) PubMed
  32. Nichols GA, Arondekar B, Garrison LP Jr. Patient characteristics and medical care costs associated with hypertriglyceridemia. Am J Cardiol. 2011 Jan 15;107(2):225-9. PubMed
  33. Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay JW, Smeeding J. Good Research Practices in Cost-Effectiveness Analyses:  A Societal Perspective:  The ISPOR Drug Cost Task Force Report—Part II.  Value in Health 13(1): 8-13, 2010.PubMed
  34. Garrison LP and Veenstra DL. The Economic Value of Innovative Treatments over the Product Life Cycle:  the Case of Targeted Trastuzumab Chemotherapy for Breast Cancer. Value in Health. 12(8): 1118-23, 2009 PubMed
  35. Garrison LP, Towse A, Bresnahan B. Assessing a Structured, Quantitative Health Outcomes Approach  to Drug Risk-Benefit Analysis, Health Affairs, 26(3):684-95, 2007. PubMed